DANIEL MEYRING: Open Payments
NPI 1649241654 · RALEIGH, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$630 in 30 payments from 9 companies in 2025. Trend: 2023 $337 · 2024 $523 · 2025 $630
Food & beverage: $630
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $189 |
| Axsome Therapeutics, Inc. | 4 | $106 |
| E.R. Squibb & Sons, L.L.C. | 5 | $100 |
| Otsuka America Pharmaceutical, Inc. | 4 | $83 |
| Teva Pharmaceuticals USA, Inc. | 2 | $43 |
| Tris Pharma Inc | 2 | $43 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $21 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $21 |
Products named: VRAYLAR, Auvelity, REXULTI, COBENFY, Dyanavel XR, AUSTEDO XR, HETLIOZ, CAPLYTA.
Industry payments across NC — which companies pay providers there.
